News BMS files Opdivo in post-surgery setting Opdivo performed better than BMS' Yervoy in clinical trial.
News BMS and Infinity aim to overcome triple negative breast canc... BMS is looking to get ahead of its rival Merck & Co. by overcoming resistance to PD-1 immunotherapy in triple negative breast cancer patients.
Views & Analysis Interview: AZ's immunotherapy gamble starts to pay off Robert Iannone, AstraZeneca's head of immune-oncology research, on the unpredictable immunotherapy market.
News Keytruda approved for bladder cancer in Europe, first to pro... Merck Sharp & Dohme’s Keytruda has been approved in Europe for metastatic urothelial carcinoma, a move which helps it catch up with its immunotherapy rivals.
News Chinese trial backs base-editing drug for thalassaemia A landmark study in China has shown that a base-editing therapy developed by CorrectSequence achieved stellar results in beta-thalassaemia.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
